Cumberland Pharmaceuticals Inc. develops, acquires and commercializes branded prescription pharmaceutical products for hospital acute care, gastroenterology and oncology markets. Company news commonly covers operating results, product-portfolio updates and regulatory developments for FDA-approved brands such as Caldolor, Sancuso and Vaprisol.
Recurring updates also address Caldolor indication activity, Sancuso educational and commercial resources, and clinical or regulatory disclosures tied to Cumberland's ifetroban programs in systemic sclerosis, Duchenne muscular dystrophy-associated cardiomyopathy and idiopathic pulmonary fibrosis. Capital-structure items, material agreements and shareholder voting matters appear alongside the company's financial and portfolio updates.
Cumberland Pharmaceuticals (NASDAQ: CPIX) reported second quarter 2020 net revenues of $9.6 million from ongoing operations, up from $9.4 million year-over-year. Total revenues were $10.3 million, boosted by $750,000 from divested product rights. The Company's financial position showed $97.5 million in total assets, $49.1 million in liabilities, and $48.5 million in shareholders' equity. Net income for Q2 was a loss of $(0.9) million, equating to $(0.06) per share, while adjusted earnings improved to $1.2 million or $0.08 per diluted share. Cumberland continued to support healthcare during COVID-19 with product supply initiatives.
Cumberland Pharmaceuticals Inc. (CPIX) will release its second quarter 2020 financial results and company update on August 11, 2020, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results. The company focuses on developing and commercializing prescription brands in hospital acute care, gastroenterology, and oncology via targeted sales forces. Their FDA-approved products include Acetadote, Caldolor, Kristalose, and more, with ongoing Phase II programs for ifetroban in DMD, SSc, and AERD.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced the results of a study published in the Journal of Orthopedic Trauma, demonstrating that Caldolor ® (ibuprofen injection) significantly reduces opioid use for pain management in orthopedic trauma patients. Conducted at a Level 1 Trauma Center, the randomized trial involved 99 patients receiving either 800 mg IV ibuprofen or a placebo. Results indicated a longer time to first narcotic medication and lower pain intensity at 8 hours in the Caldolor group. This research highlights a potential alternative to opioids in emergency pain management.